Wendell David Associates Has Lowered Stericycle (SRCL) Holding; Antares Pharma (ATRS) Shorts Increased By 10.61%

May 24, 2018 - By Vivian Park

Stericycle, Inc. (NASDAQ:SRCL) Logo

Antares Pharma Inc (NASDAQ:ATRS) had an increase of 10.61% in short interest. ATRS’s SI was 5.79 million shares in May as released by FINRA. Its up 10.61% from 5.23 million shares previously. With 1.52M avg volume, 4 days are for Antares Pharma Inc (NASDAQ:ATRS)’s short sellers to cover ATRS’s short positions. The SI to Antares Pharma Inc’s float is 4.08%. The stock increased 1.20% or $0.03 during the last trading session, reaching $2.53. About 778,675 shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has declined 23.10% since May 24, 2017 and is downtrending. It has underperformed by 34.65% the S&P500.

Wendell David Associates Inc decreased Stericycle (SRCL) stake by 26.08% reported in 2017Q4 SEC filing. Wendell David Associates Inc sold 6,575 shares as Stericycle (SRCL)’s stock declined 13.72%. The Wendell David Associates Inc holds 18,632 shares with $1.27 million value, down from 25,207 last quarter. Stericycle now has $5.43 billion valuation. The stock decreased 0.22% or $0.14 during the last trading session, reaching $63.45. About 398,620 shares traded. Stericycle, Inc. (NASDAQ:SRCL) has declined 27.78% since May 24, 2017 and is downtrending. It has underperformed by 39.33% the S&P500.

Since March 1, 2018, it had 1 buy, and 1 insider sale for $211,208 activity. $837,118 worth of stock was sold by Brown Thomas D on Wednesday, May 16. SCHULER JACK W bought $625,910 worth of stock or 10,000 shares.

Analysts await Stericycle, Inc. (NASDAQ:SRCL) to report earnings on August, 2. They expect $1.13 EPS, down 1.74% or $0.02 from last year’s $1.15 per share. SRCL’s profit will be $96.70M for 14.04 P/E if the $1.13 EPS becomes a reality. After $1.21 actual EPS reported by Stericycle, Inc. for the previous quarter, Wall Street now forecasts -6.61% negative EPS growth.

More notable recent Stericycle, Inc. (NASDAQ:SRCL) news were published by: Seekingalpha.com which released: “Stericycle Muddling Through Difficulties” on May 22, 2018, also Globenewswire.com with their article: “Stericycle, Inc. Reports Results for the First Quarter 2018” published on May 03, 2018, Seekingalpha.com published: “Stericycle: Looks To Have Turned The Corner” on May 15, 2018. More interesting news about Stericycle, Inc. (NASDAQ:SRCL) were released by: Globenewswire.com and their article: “Stericycle Declares Dividend On Mandatory Convertible Preferred Stock” published on May 05, 2018 as well as Seekingalpha.com‘s news article titled: “Stericycle, Inc. 2018 Q1 – Results – Earnings Call Slides” with publication date: May 03, 2018.

Among 16 analysts covering Stericycle (NASDAQ:SRCL), 6 have Buy rating, 2 Sell and 8 Hold. Therefore 38% are positive. Stericycle had 58 analyst reports since August 14, 2015 according to SRatingsIntel. As per Monday, November 30, the company rating was maintained by RBC Capital Markets. The rating was maintained by Wedbush on Thursday, September 22 with “Neutral”. On Wednesday, October 11 the stock rating was maintained by RBC Capital Markets with “Sell”. On Monday, May 2 the stock rating was maintained by Wedbush with “Neutral”. The firm earned “Neutral” rating on Friday, October 23 by Robert W. Baird. The firm earned “Hold” rating on Tuesday, February 13 by Robert W. Baird. The company was maintained on Friday, October 23 by Stifel Nicolaus. Jefferies maintained Stericycle, Inc. (NASDAQ:SRCL) rating on Wednesday, January 31. Jefferies has “Buy” rating and $85.0 target. The rating was maintained by Jefferies on Friday, July 7 with “Buy”. As per Friday, October 28, the company rating was upgraded by Stifel Nicolaus.

Investors sentiment decreased to 0.7 in Q4 2017. Its down 0.19, from 0.89 in 2017Q3. It is negative, as 75 investors sold SRCL shares while 177 reduced holdings. 50 funds opened positions while 126 raised stakes. 76.99 million shares or 1.32% less from 78.02 million shares in 2017Q3 were reported. 28,114 were accumulated by Vision Management Incorporated. 1832 Asset Lp has invested 0.01% in Stericycle, Inc. (NASDAQ:SRCL). Virtus Advisers Incorporated accumulated 32,632 shares. Glenmede Na reported 1,058 shares. Citigroup holds 0% or 15,297 shares. Ironwood Counsel Ltd Liability has invested 0.33% in Stericycle, Inc. (NASDAQ:SRCL). Robeco Institutional Asset Bv holds 4,197 shares or 0% of its portfolio. Liberty Mutual Group Asset Mgmt holds 0.01% or 3,401 shares. Royal Comml Bank Of Canada owns 370,464 shares or 0.01% of their US portfolio. Exchange Capital has invested 0.95% in Stericycle, Inc. (NASDAQ:SRCL). Plante Moran Advisors Limited Co accumulated 116 shares or 0% of the stock. Stratos Wealth Ltd invested 0.14% in Stericycle, Inc. (NASDAQ:SRCL). Tru Of Vermont invested in 0% or 326 shares. California State Teachers Retirement owns 138,949 shares for 0.02% of their portfolio. Nomura Hldgs holds 0% of its portfolio in Stericycle, Inc. (NASDAQ:SRCL) for 5,500 shares.

More recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Seekingalpha.com which released: “Antares Pharma: Excellent Risk-Reward Profile” on May 22, 2018. Also Globenewswire.com published the news titled: “Antares Pharma Reports First Quarter 2018 Operating and Financial Results” on May 08, 2018. Seekingalpha.com‘s news article titled: “Antares Pharma’s (ATRS) CEO Robert Apple on Q1 2018 Results – Earnings Call Transcript” with publication date: May 08, 2018 was also an interesting one.

Investors sentiment decreased to 1.16 in Q4 2017. Its down 0.13, from 1.29 in 2017Q3. It is negative, as 9 investors sold Antares Pharma, Inc. shares while 29 reduced holdings. 19 funds opened positions while 25 raised stakes. 54.49 million shares or 1.74% more from 53.56 million shares in 2017Q3 were reported. Rhumbline Advisers stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Broadfin Capital Lc has 4.54M shares. Goldman Sachs Gru invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Voya Mngmt Ltd invested in 0% or 65,073 shares. Retail Bank Of Ny Mellon Corporation reported 545,786 shares. Moore Cap Management Lp holds 0.01% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 140,000 shares. Georgia-based Invesco Ltd has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). California-based Wells Fargo And Mn has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Hanson Mcclain holds 200 shares or 0% of its portfolio. Royal Bank & Trust Of Canada has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Fuller And Thaler Asset Management holds 554,000 shares or 0.01% of its portfolio. Raymond James Advisors has invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Manufacturers Life Ins The holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 118,846 shares. Tower Ltd Liability Company (Trc) holds 0% in Antares Pharma, Inc. (NASDAQ:ATRS) or 4,416 shares. Oppenheimer & Comm accumulated 25,600 shares.

Since May 9, 2018, it had 0 insider buys, and 5 selling transactions for $2.29 million activity. 21,062 shares were sold by GONELLA JACQUES, worth $54,761.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $396.77 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 14 analyst reports since March 9, 2016 according to SRatingsIntel. Jefferies maintained Antares Pharma, Inc. (NASDAQ:ATRS) on Monday, August 7 with “Buy” rating. H.C. Wainwright initiated the shares of ATRS in report on Friday, June 23 with “Buy” rating. As per Wednesday, March 14, the company rating was maintained by H.C. Wainwright. The rating was initiated by H.C. Wainwright with “Buy” on Friday, September 8. H.C. Wainwright maintained the shares of ATRS in report on Thursday, February 15 with “Buy” rating. H.C. Wainwright maintained the shares of ATRS in report on Tuesday, May 8 with “Buy” rating. Piper Jaffray maintained the shares of ATRS in report on Tuesday, July 25 with “Buy” rating. H.C. Wainwright maintained the shares of ATRS in report on Wednesday, November 8 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Tuesday, October 10. On Tuesday, March 27 the stock rating was maintained by H.C. Wainwright with “Buy”.

Stericycle, Inc. (NASDAQ:SRCL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts